Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Schumer Calls On HHS Head Azar To Resign

Executive Summary

Chuck Schumer, the top Democratic senator, is calling on HHS secretary Alex Azar to resign, accusing him of putting politics over public health.

You may also be interested in...



Trust Us: Is Pharma’s COVID-19 Vaccine Pledge Convincing?

Missteps on convalescent plasma and the revoked authorization of hydroxychloroquine – paired with US president Trump’s cheerleading for the rapid approval of a COVID-19 vaccine – has eroded public trust in the US FDA. Can a safety and efficacy pledge from vaccine developers tamp down public skepticism?

$2Bn Golden Egg: 8 Manufacturers Will Share Billions To Make Ventilators For US Govt

Seven companies – GE, Medtronic, ResMed, Hill-Rom, Vyaire, Hamilton Medical and Zoll – will manufacture 64,431 medical ventilators under the Defense Production Act at a cost of more than $1.4bn, the US Department of Health and Human Services said on 13 April. That figure, when combined with the $646.7m recently awarded to Royal Philips to make 45,500 vents, means the US government will spend more than $2bn on the devices.

New HHS Chief Alex Azar Supports LDT Regulation, Cost-Saving Bundles

Alex Azar was confirmed as the next secretary of Health and Human Services with strong industry support. Azar comes to the role with some homework to do on key FDA medtech policies, but has expressed support for risk-based regulation of lab-developed tests and cost-saving bundled-payment models.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel